Skip to main content

Advertisement

SpringerLink
Log in

The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

This study assessed the efficacy and safety of onabotulinumtoxinA according to injection site for treatment of overactive bladder.

Methods

A systematic literature review located randomized controlled trials of onabotulinumtoxinA treatment for neurogenic detrusor overactive bladder and idiopathic overactive bladder in adults. We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the Ovid platform. Meta-analysis was based on Cochrane Review Methods.

Results

Eight studies (419 participants) were included. Trigone-including injection demonstrated a significant improvement in symptom score (SMD = − 0.53, 95% CI − 1.04 to − 0.02, P = 0.04, I 2 = 78%), higher complete dryness rates (OR = 2.19 patients, 95% CI 1.32–3.63, P = 0.002, I 2 = 41%), and lower frequency of incontinence episodes (WMD = − 0.85 per day, 95% CI − 1.55 to − 0.16, P = 0.02, I 2 = 87%) in patients. Comparing trigone-including injection to trigone-sparing injection, lower detrusor pressure (WMD = − 2.55 cm H2O, 95% CI − 4.16 to − 0.95, P = 0.002, I 2 = 0%) and higher volume at first desire to void (WMD = 17.54 ml, 95% CI 1.00–34.07, P = 0.04, I 2 = 0%) were observed with trigone-including injection. Between intradetrusor and suburothelial injection sites, there were no differences in efficacy or safety regarding the incidence of vesicoureteral reflux, hematuria, general weakness, bladder discomfort, large post-void residual, and urinary tract infection.

Conclusion

Trigone-including onabotulinumtoxinA injection has superior efficacy to trigone-sparing injection without increased complications. The depth of injection does not influence the efficacy or safety of onabotulinumtoxinA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21(2):167–178

    Article  PubMed  Google Scholar 

  2. Sacco E, Tienforti D, D’Addessi A, Pinto F, Racioppi M, Totaro A, D’Agostino D, Marangi F, Bassi P (2010) Social, economic, and health utility considerations in the treatment of overactive bladder. Open Access J Urol 2:11–24

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306–1314. https://doi.org/10.1016/j.eururo.2006.09.019 (discussion 1314–1305)

    Article  PubMed  Google Scholar 

  4. Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD (2009) The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care 15(4 Suppl):S90–S97

    PubMed  Google Scholar 

  5. Garely AD, Burrows LJ (2002) Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 3(7):827–833. https://doi.org/10.1517/14656566.3.7.827

    Article  CAS  PubMed  Google Scholar 

  6. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20(6):327–336. https://doi.org/10.1007/s00345-002-0301-4

    CAS  PubMed  Google Scholar 

  7. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(5A Suppl):33–46 (discussion 50)

    Article  CAS  PubMed  Google Scholar 

  8. Cameron AP (2010) Pharmacologic therapy for the neurogenic bladder. Urol Clinic N Am 37(4):495–506. https://doi.org/10.1016/j.ucl.2010.06.004

    Article  Google Scholar 

  9. Brostrom S, Hallas J (2009) Persistence of antimuscarinic drug use. Eur J Clin Pharmacol 65(3):309–314. https://doi.org/10.1007/s00228-008-0600-9

    Article  CAS  PubMed  Google Scholar 

  10. Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65(5):567–585. https://doi.org/10.1111/j.1742-1241.2010.02626.x

    Article  CAS  PubMed  Google Scholar 

  11. Grosse J, Kramer G, Stohrer M (2005) Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 47(5):653–659. https://doi.org/10.1016/j.eururo.2004.11.009

    Article  CAS  PubMed  Google Scholar 

  12. Bagi P, Biering-Sorensen F (2004) Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 38(6):495–498. https://doi.org/10.1080/00365590410015867

    Article  CAS  PubMed  Google Scholar 

  13. Jundt K, Schreyer K, Friese K, Peschers U (2011) Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 284(3):663–666. https://doi.org/10.1007/s00404-010-1720-x

    Article  CAS  PubMed  Google Scholar 

  14. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://handbook.cochrane.org. Accessed Apr 2017

  15. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(6):557–560. https://doi.org/10.1136/bmj.327.7414.557

    Article  PubMed  PubMed Central  Google Scholar 

  16. Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, Xiangrong D, Liling Z, Maping H, Qingqing L, Qiuling L, Jiebing H, Tanghai H (2016) Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord 54(1):46–50. https://doi.org/10.1038/sc.2015.143

    Article  CAS  PubMed  Google Scholar 

  17. Huang M, Chen H, Jiang C, Xie K, Tang P, Ou R, Zeng J, Liu Q, Li Q, Huang J, Huang T, Zeng W (2016) Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J Rehabil Med 48(8):683–687. https://doi.org/10.2340/16501977-2132

    Article  PubMed  Google Scholar 

  18. Kuo HC (2011) Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn 30(7):1242–1248. https://doi.org/10.1002/nau.21054

    PubMed  Google Scholar 

  19. Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, Grainger R, Thornhill JA (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61(5):928–935. https://doi.org/10.1016/j.eururo.2011.10.043

    Article  CAS  PubMed  Google Scholar 

  20. Abdel-Meguid TA (2010) Botulinum toxin-A injections into neurogenic overactive bladder—to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 184(6):2423–2428. https://doi.org/10.1016/j.juro.2010.08.028

    Article  CAS  PubMed  Google Scholar 

  21. Krhut J, Samal V, Nemec D, Zvara P (2012) Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord 50(12):904–907. https://doi.org/10.1038/sc.2012.76

    Article  CAS  PubMed  Google Scholar 

  22. Kuo HC (2007) Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 178(4 Pt 1):1359–1363. https://doi.org/10.1016/j.juro.2007.05.136

    Article  PubMed  Google Scholar 

  23. Samal V, Mecl J, Sram J (2013) Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int 91(4):423–428. https://doi.org/10.1159/000350247

    Article  CAS  PubMed  Google Scholar 

  24. Purves JT, Spruill L, Rovner E, Borisko E, McCants A, Mugo E, Wingard A, Trusk TC, Bacro T, Hughes FM Jr (2017) A three dimensional nerve map of human bladder trigone. Neurourol Urodyn 36(4):1015–1019. https://doi.org/10.1002/nau.23049

    Article  PubMed  Google Scholar 

  25. Andersson KE (2002) Bladder activation: afferent mechanisms. Urology 59(5 Suppl 1):43–50

    Article  PubMed  Google Scholar 

  26. Klein LA (1988) Urge incontinence can be a disease of bladder sensors. J Urol 139(5):1010–1014

    Article  CAS  PubMed  Google Scholar 

  27. Kuo HC (2006) Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 68(5):993–997. https://doi.org/10.1016/j.urology.2006.05.054 (discussion 997–998)

    Article  PubMed  Google Scholar 

  28. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416–2422. https://doi.org/10.1016/j.juro.2010.08.021

    Article  CAS  PubMed  Google Scholar 

  29. Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B (2009) A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 27(3):397–403. https://doi.org/10.1007/s00345-008-0362-0

    Article  CAS  PubMed  Google Scholar 

  30. Kjaergard LL, Villumsen J, Gluud C (2001) Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 135(11):982–989

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Hospital funding only by the research fund of Hanyang University (HY-2017).

Author information

Authors and Affiliations

  1. Department of Urology, College of Medicine, Hanyang University, Seoul, Korea

    Jung Ki Jo & Yong Tae Kim

  2. Department of Anesthesiology and Pain Medicine, College of Medicine, Hanyang University, Seoul, Korea

    Kyu Nam Kim & Dong Won Kim

  3. Department of Anesthesiology and Pain Medicine, Hanyang University Hospital, 222, Wangsimni-ro, Seongdonggu, Seoul, 133-792, Republic of Korea

    Kyu Nam Kim, Ji Yoon Kim & Ji Yeon Kim

Authors
  1. Jung Ki Jo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kyu Nam Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong Won Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yong Tae Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ji Yoon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ji Yeon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JKJ: study design, data acquisition, analysis and interpretation of data, and writing of the article; KNK: study design, data acquisition, analysis and interpretation of data, and writing of the article; DWK: data acquisition and interpretation of data; YTK: data acquisition; JYK: organizing data; JYK: organizing data and preparing manuscript.

Corresponding author

Correspondence to Kyu Nam Kim.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jo, J.K., Kim, K.N., Kim, D.W. et al. The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol 36, 305–317 (2018). https://doi.org/10.1007/s00345-017-2121-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-017-2121-6

Keywords

Search

Navigation